Yale receives renewed lung cancer SPORE grant from NCI

As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon

While every agency under HHS, particularly FDA, has seen historic leadership shakeups and massive cuts to personnel and funding over the course of the second Trump administration—NCI has been spared, even getting a small raise, under the direction of NCI Director Anthony Letai.

May 27, 2026

Capitol Hill NCI

NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing

NCI has been getting what seems to be less austere treatment compared to its NIH counterparts.

USPSTF leaders John Wong and Esa Davis fired by Kennedy, leaving the panel rudderless

Esa M. Davis and John B. Wong have been fired from U.S. Preventive Services Task Force by HHS Secretary Robert F. Kennedy Jr.

May 22, 2026

Vol.52 No.20

By Claire Marie Porter

Clinical Roundup

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Clinical Roundup

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Yale receives renewed lung cancer SPORE grant from NCI

YOU MAY BE INTERESTED IN

As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon

NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing

USPSTF leaders John Wong and Esa Davis fired by Kennedy, leaving the panel rudderless

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Renew today!

Subscriber content

Never miss an issue!

Login